Ethyreal starts up with $101M and takes aim at a pair of immune diseases

AI Summary

Ethyreal, a US-based startup, has secured $101 million in funding to develop treatments targeting thyroid eye disease and related immune conditions. Their medicine aims to offer a novel approach compared to existing treatments.

The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.